Disparities in Incidence of Human Immunodeficiency Virus Infection Among Black and White Women — United States, 2010–2016
Weekly / May 10, 2019 / 68(18);416–418
Erin L.P. Bradley, PhD1,2; Austin M. Williams, PhD3; Shana Green, PhD1,2; Ashley C. Lima, PhD1,2; Angelica Geter, PhD1,2; Harrell W. Chesson, PhD3; Donna Hubbard McCree, PhD1 (View author affiliations)View suggested citation
What is already known about this topic?
Rates of human immunodeficiency virus (HIV) infection among all women have declined since 2010, but rates among black women remain higher than do those among white women.
What is added by this report?
A population attributable proportion analysis found that in 2016, an estimated 3,900 of 4,200 (93%) incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women.
What are the implication for public health practice?
Reducing racial disparities among women is needed to achieve broader HIV control goals. Addressing social and structural determinants of health and applying tailored strategies to reduce HIV incidence in black women and their partners are important elements to achieving health equity.
Incident human immunodeficiency virus (HIV) infections among adolescent females and women declined during 2010–2016, with the largest decrease (21%) occurring among black women (1). However, in 2016, although black women accounted for 13% of the U.S. female population, 60% of new HIV infections among women were in black women, indicating persisting disparities (1). CDC used the population attributable proportion (PAP) disparity measure to describe the proportional decrease in HIV infection among black and white women combined that would be realized if the group with the higher rate (blacks) had the same rate as did the group with the lower rate (whites) (2). Analyses indicated that an estimated 3,900 of 4,200 (93%) incident HIV infections among black women in 2016 would not have occurred if rates were the same for black and white women. The PAP disparity measure decreased from 0.75 in 2010 to 0.70 in 2016, suggesting that if incidence rates for black women were the same as those for white women, the annual number of incident HIV infections among black and white women would have been 75% lower in 2010 and 70% lower in 2016. Continued efforts are needed to identify and address social and structural determinants associated with HIV-related disparities to eliminate these disparities and decrease HIV incidence among black women.
CDC calculated the PAP disparity measure to assess trends in HIV infection disparities among black and white women in the United States from 2010 to 2016. HIV incidence and prevalence estimates for women and adolescent females aged ≥13 years from an HIV Supplemental Surveillance Report (1) were used to compare estimated incidence with the incidence had there been no racial disparity between blacks and whites (black-white disparity). The PAP disparity measure was calculated as the number of excess incident infections among black females divided by the total number of estimated incident infections among black and white females combined. Excess incident infections were determined as the estimated number of incident infections among black females minus the hypothetical number of incident infections (infections among black females in the absence of a black-white rate disparity). The hypothetical number of incident infections was obtained by dividing the HIV incidence rate in white females by 100,000 and then multiplying by the number of HIV-negative black females. To increase precision in the analyses because incident infection counts in the surveillance report were rounded to the nearest hundred, the estimated number of incident HIV infections was derived by dividing the surveillance report rate by 100,000, then multiplying by the number of females aged ≥13 years. Rates of HIV infection were defined as the estimated number of incident infections divided by the number of HIV-negative females aged ≥13 years, then multiplied by 100,000. This calculation was carried out for each year from 2010 to 2016. To assess changes in the PAP disparity measure between the beginning and the end of the study period, a z-statistic was calculated to test for statistically significant differences between the 2010 and 2016 measures. The z-statistic was calculated as the average difference between the 2016 and 2010 PAP disparity measures in the simulated data divided by the standard error of those differences. Simulations consisted of 10,000 calculations of the annual PAP measures, each using a random draw of the HIV incidence rate from a normal distribution (approximated using the relative standard errors from the surveillance report) (3).
From 2010 to 2016, the estimated incidence of HIV infection among black women and adolescent females decreased from 32.5 per 100,000 persons to 24.4; the rate among white women and adolescent females did not differ in 2016 (1.6) compared with that in 2010 (1.6) and ranged from 1.4–1.7 during that time. The PAP disparity measure decreased from 0.75 in 2010 to 0.70 in 2016. This change suggests that if incidence rates for black women were the same as were those for white women, the annual number of incident cases of HIV infection among black and white women would have been 75% lower in 2010 and 70% lower in 2016 (Table). The 7% decrease in the PAP disparity measure from 2010 to 2016 (p = 0.15) indicates that the percentage of incident HIV infections attributable to racial disparities between black and white women decreased by about 7% over this period. Thus, in 2016, an estimated 3,900 of 4,200 (93%) incident HIV infections among black women would not have occurred if rates were the same for black and white women.
The declines in incidence of HIV infection among black women and adolescent females signal some progress toward reducing racial disparities among women, and these findings are consistent with previous research that indicated reductions in racial/ethnic disparities in diagnosis of HIV infection among women during 2010–2014 using different measures of disparity (absolute rate difference, diagnosis disparity ratio, and index of disparity) (4). However, notable black-white disparities among women persist. In 2016, an estimated 93% of incident HIV infections among black women would not have occurred if the incidence rate for black women were as low as the rate for white women. Estimates of the annual PAP disparity measure during 2010–2016 suggest that eliminating black-white disparities in incident HIV infections among women and adolescent females would have achieved a decrease in overall incidence among black and white women of 75% in 2010 and 70% in 2016. This finding highlights the contribution of racial/ethnic disparities to overall HIV infection rates among women and adolescent females and underscores the importance of further reducing, or eliminating, these differences.
Reducing and monitoring HIV-related disparities are important national goals (5). Tailored strategies to reduce disparities in incidence among women should address social and structural determinants, including inequitable access to health care, HIV-related stigma, and comparatively high background prevalence of certain sexually transmitted infections (6,7), that increase the risk for HIV infection among black women. Because most HIV infections among black women occur through heterosexual transmission (1), strategies that also effectively engage heterosexual and bisexual men are important. Social and structural determinants create or sustain disparities in HIV infection, treatment, and care. For example, compared with their white counterparts, black women and men experience longer delays in diagnosis (8) and are less likely to be virally suppressed (i.e., <200 copies of viral RNA per mL of blood) (9,10). Targeted measures that address reducing transmission through viral suppression and preventing acquisition through biomedical and behavioral interventions (e.g., preexposure prophylaxis [PrEP] and condom use; and providing adequate treatment once HIV infection is diagnosed) will play important roles in reducing disparities.
The findings in this report are subject to at least five limitations. First, estimates of HIV incidence are subject to model assumptions and data completeness (1). Second, only one measure of disparity was used, limiting a more comprehensive analysis of racial/ethnic disparities in incidence of HIV infection among women and adolescent females. Using other measures of disparity could provide alternative results. Third, the p-value calculated for the 7% change in the PAP might be overestimated because it assumed no correlation in the error of estimated incidence within racial groups over time. This implies that the error in estimating the 2010 incidence among black women is unrelated to the error in estimating the 2016 incidence among black women. Fourth, although the PAP disparity measure has a straightforward interpretation and quantifies excess HIV infections among black females, this study does not yield additional insight into what structural or policy changes are needed to eliminate disparities. Finally, incidence in only two racial groups was compared, whereas disparities might exist among other racial/ethnic groups.
Despite these limitations, findings from the PAP disparity measure analyses enhance the measurement of HIV disparities among women and adolescent females by quantifying the number of incident HIV infections that might have been prevented in the absence of racial disparities. This information lends support for strengthening HIV prevention and care efforts for heterosexual black females and males to continue progress toward closing the gap in racial disparities in HIV infection among women. Such gains are needed to achieve the U.S. Department of Health and Human Services’ goal of ending the HIV epidemic in the United States by 2030* and prevent deaths related to acquired immunodeficiency syndrome.
Felicia Hardnett, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.
Corresponding author: Donna Hubbard McCree, firstname.lastname@example.org, 404-639-1834.
1Divsion of HIV/AIDS Prevention, National Center for HIV/AIDS, STD and TB Prevention CDC; 2Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee; 3Division of STD Prevention, National Center for HIV/AIDS, STD and TB Prevention, CDC.
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- CDC. Estimated HIV incidence and prevalence in the United States, 2010–2016. HIV surveillance supplemental report, vol. 24, no. 1. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-24-1.pdfpdf icon
- Chesson HW, Patel CG, Gift TL, Aral SO. Trends in selected measures of racial and ethnic disparities in gonorrhea and syphilis in the United States, 1981–2013. Sex Transm Dis 2016;43:661–7. CrossRefexternal icon PubMedexternal icon
- Keppel KG, Pearcy JN, Klein RJ. Measuring progress in Healthy People 2010. Health People 2010 statistical notes, no. 25. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2004. https://www.cdc.gov/nchs/data/statnt/statnt25.pdfpdf icon
- McCree DH, Sutton M, Bradley E, Harris N. Changes in the disparity of HIV diagnosis rates among black women—United States, 2010–2014. MMWR Morb Mortal Wkly Rep 2017;66:104–6. CrossRefexternal icon PubMedexternal icon
- White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States: updated to 2020. Washington, DC: White House Office of National AIDS Policy; 2015. https://files.hiv.gov/s3fs-public/nhas-update.pdfpdf iconexternal icon
- Aral SO, Adimora AA, Fenton KA. Understanding and responding to disparities in HIV and other sexually transmitted infections in African Americans. Lancet 2008;372:337–40. CrossRefexternal icon PubMedexternal icon
- Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999;75:3–17. CrossRefexternal icon PubMedexternal icon
- Dailey AF, Hoots BE, Hall HI, et al. Vital signs: human immunodeficiency virus testing and diagnosis delays—United States. MMWR Morb Mortal Wkly Rep 2017;66:1300–6. CrossRefexternal icon PubMedexternal icon
- Crepaz N, Tang T, Marks G, Hall HI. Viral suppression patterns among persons in the United States with diagnosed HIV infection in 2014. Ann Intern Med 2017;167:446–7. CrossRefexternal icon PubMedexternal icon
- Crepaz N, Dong X, Wang X, Hernandez AL, Hall HI. Racial and ethnic disparities in sustained viral suppression and transmission risk potential among persons receiving HIV care—United States, 2014. MMWR Morb Mortal Wkly Rep 2018;67:113–8. CrossRefexternal icon PubMedexternal icon
Suggested citation for this article: Bradley EL, Williams AM, Green S, et al. Disparities in Incidence of Human Immunodeficiency Virus Infection Among Black and White Women — United States, 2010–2016. MMWR Morb Mortal Wkly Rep 2019;68:416–418. DOI: http://dx.doi.org/10.15585/mmwr.mm6818a3external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to email@example.com.